تداخلات ميسالازين

If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (نشرة ميسالازين، التداخلات الدوائية)

Intervention: The concomitant use of indomethacin with other NSAIDs or salicylates, especially diflunisal, is not recommended. (نشرة إندوميثاسين، التداخلات الدوائية)

Intervention: The concomitant use of oxaprozin with other NSAIDs or salicylates is not recommended. (نشرة أوكسابروزين، التداخلات الدوائية)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (نشرة ميسالازين، التداخلات الدوائية)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (نشرة إيبوبروفين، التداخلات الدوائية)

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (نشرة إيبوبروفين وفاموتيدين، التداخلات الدوائية)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (نشرة باراسيتامول وإيبوبروفين، التداخلات الدوائية)

In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد، التحذيرات)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (نشرة بيروكسيكام، التداخلات الدوائية)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (نشرة ميسالازين، التداخلات الدوائية)

Intervention: The concomitant use of mefenamic acid with other NSAIDs or salicylates is not recommended. (نشرة حمض الميفيناميك، التداخلات الدوائية)

Intervention: The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended. (نشرة ديكلوفيناك، التداخلات الدوائية)

Intervention: The concomitant use of diclofenac sodium/misoprostol with other NSAIDs or salicylates is not recommended. (نشرة ديكلوفيناك وميزوبروستول، التداخلات الدوائية)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (نشرة سوماتريبتان ونابروكسين، التداخلات الدوائية)

Intervention: The concomitant use of Celecoxib with other NSAIDs or salicylates is not recommended. (نشرة سيليكوكسيب، التداخلات الدوائية)

Intervention: The concomitant use of flurbiprofen with other NSAIDs or salicylates is not recommended. (نشرة فلوربيبروفين، التداخلات الدوائية)

Contraindications: ANTICHOLIUM ® should not be used in the presence of hypersensitivity to physostigmine salicylate, bronchial asthma, ulcers associated with tissue destruction (gangrene), coronary heart disease, constipation (mechanical obstipation), mechanical ischuria (urinary retention), hereditary form of muscle atrophy (myotonic dystrophy), closed traumatic… (نشرة فيزوستيغمين، موانع الاستعمال)

Intervention: The concomitant use of fenoprofen with other NSAIDs or salicylates is not recommended. (نشرة فينوبروفين، التداخلات الدوائية)

Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . (نشرة ميسالازين، التداخلات الدوائية)

If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (نشرة ميسالازين، التداخلات الدوائية)

Intervention: The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended. (نشرة ميلوكسيكام، التداخلات الدوائية)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (نشرة نابروكسين، التداخلات الدوائية)

Intervention: The concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with other NSAIDs or salicylates is not recommended. (نشرة نابروكسين وإيزوميبرازول، التداخلات الدوائية)

The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (نشرة هيدروكودون وإيبوبروفين، التداخلات الدوائية)

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. (نشرة أدابالين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين أسبارت، التداخلات الدوائية)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (نشرة إنسولين ديتيمير، التداخلات الدوائية)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

…agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically… (نشرة إنسولين عادي (بشري)، التداخلات الدوائية)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. (نشرة إنسولين غلارجين، التداخلات الدوائية)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين ليسبرو، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid and temazepam. (نشرة إيتونوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an exacerbation of ulcerative colitis; monitor for worsening symptoms; discontinue treatment if acute intolerance syndrome is suspected. (نشرة بالسالازيد، التحذيرات والاحتياطات)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (نشرة بروموكريبتين، التداخلات الدوائية)

NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (نشرة بريدنيزولون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

• Rare instances of acid-base alterations have occurred with high-dose salicylate therapy. (نشرة برينزولاميد، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (نشرة بيوغليتازون وغليميبيريد، التداخلات الدوائية)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (نشرة تريامسينولون، التداخلات الدوائية)

Nonsteroidal Anti-Inflammatory Drugs Because torsemide and salicylates compete for secretion by renal tubules, patients receiving high doses of salicylates may experience salicylate toxicity when torsemide is concomitantly administered. (نشرة توراسيميد، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (نشرة دورزولاميد، التداخلات الدوائية)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (نشرة دورزولاميد وتيمولول، التداخلات الدوائية)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (نشرة ديسوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (نشرة ديكساميثازون، التداخلات الدوائية)

Concomitant Use of Aspirin or Other Salicylates Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warnings and Precautions (5.4) ] , which can increase the risk of salicylate toxicity. (نشرة ديكلورفيناميد، التحذيرات والاحتياطات)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Conversely, agents such as indomethacin, probenecid and salicylates may displace sulfonamides from plasma albumin and increase the concentrations of free drug in plasma. (نشرة سلفاديازين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly with salicylates. (نشرة غريزيوفولفين، التداخلات الدوائية)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (نشرة غليبنكلاميد، التداخلات الدوائية)

…antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor… (نشرة غليبيزيد، التداخلات الدوائية)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (نشرة غليبيزيد وميتفورمين، الاحتياطات)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (نشرة غليميبيريد، التداخلات الدوائية)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (نشرة فلودروكورتيزون، التداخلات الدوائية)

Coadministration of aspirin 150 mg/day with multiple daily doses of TRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Clinical Pharmacology (12.3) ] . (نشرة فورتيوكسيتين، التداخلات الدوائية)

• Salicylates : Risk of salicylate toxicity ( 7.1 ) (نشرة فوروسيميد، التداخلات الدوائية)

…sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin,… (نشرة فوسفينيتوين، التداخلات الدوائية)

…sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antacids Antacids may affect absorption of phenytoin. (نشرة فينيتوين، التداخلات الدوائية)

Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (نشرة فينيل أسيتات الصوديوم وبنزوات الصوديوم، التحذيرات والاحتياطات)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

An initial increase in serum FT 4 is followed by return of FT 4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T 4 levels may decrease by as much as 30%. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Other Drugs Clinical effect Concomitant use of CHCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. (نشرة ليفونورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. (نشرة ليوثيرونين، التداخلات الدوائية)

Salicylates And Other Non-Steroidal Anti-Inflammatory Drugs May decrease the antihypertensive effects of metolazone tablets, USP. (نشرة ميتولازون، التداخلات الدوائية)

Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate, including XATMEP. (نشرة ميثوتريكسات، التداخلات الدوائية)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (نشرة ميثيل بريدنيزولون، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

…with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan,… (نشرة ناتيغلينيد، التداخلات الدوائية)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (نشرة نورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (نشرة نورجيستيمات وإيثينيل إستراديول، التداخلات الدوائية)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam. (نشرة نوريلجيسترومين وإيثينيل إستراديول، التداخلات الدوائية)

In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. (نشرة نيزاتيدين، التداخلات الدوائية)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (نشرة هيالورونيداز، التداخلات الدوائية)

The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. (نشرة هيدروكورتيزون، التداخلات الدوائية)

In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam. (نشرة إنتاكابون، الاحتياطات)

These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. (نشرة إينوكسابارين، التداخلات الدوائية)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (نشرة ريباغلينيد، التداخلات الدوائية)

Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. (نشرة ميسالازين، التحذيرات والاحتياطات)